Ani Pharmaceuticals reported $59.78M in Operating Expenses for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Aerie Pharmaceuticals AERI:US $ 60.59M 3.7M
Ani Pharmaceuticals ANIP:US $ 59.78M 2.16M
Biodelivery Sciences International BDSI:US $ 33.65M 1.35M
Depomed DEPO:US $ 39.38M 23.11M
Eli Lilly And LLY:US $ 4302.6M 33.6M
Emergent Biosolutions EBS:US $ 268.7M 64.6M
Endo International Ordinary Shares ENDP:US $ 573.09M 29.12M
Novartis NVS:US 10.13B 856M
Perrigo Ordinary Shares PRGO:US $ 1329.2M 227.5M
Teva Pharmaceutical Industries TEVA:US 8.32B 4.62B